306 related articles for article (PubMed ID: 9343327)
1. Significant reduction in the rate of false-negative cervical smears with neural network-based technology (PAPNET Testing System).
Koss LG; Sherman ME; Cohen MB; Anes AR; Darragh TM; Lemos LB; McClellan BJ; Rosenthal DL; Keyhani-Rofagha S; Schreiber K; Valente PT
Hum Pathol; 1997 Oct; 28(10):1196-203. PubMed ID: 9343327
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the PAPNET cytologic screening system for quality control of cervical smears.
Koss LG; Lin E; Schreiber K; Elgert P; Mango L
Am J Clin Pathol; 1994 Feb; 101(2):220-9. PubMed ID: 8116579
[TBL] [Abstract][Full Text] [Related]
3. PAPNET-assisted rescreening of cervical smears: cost and accuracy compared with a 100% manual rescreening strategy.
O'Leary TJ; Tellado M; Buckner SB; Ali IS; Stevens A; Ollayos CW
JAMA; 1998 Jan; 279(3):235-7. PubMed ID: 9438746
[TBL] [Abstract][Full Text] [Related]
4. Atypical squamous cells of undetermined significance: a comparative review of original and automated rescreen diagnosis of cervicovaginal smears with long term follow-up.
Stastny JF; Remmers RE; London WB; Pedigo MA; Cahill LA; Ryan M; Frable WJ
Cancer; 1997 Dec; 81(6):348-53. PubMed ID: 9438460
[TBL] [Abstract][Full Text] [Related]
5. The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: II. Prospective and archival sensitivity studies.
Patten SF; Lee JS; Wilbur DC; Bonfiglio TA; Colgan TJ; Richart RM; Cramer H; Moinuddin S
Cancer; 1997 Dec; 81(6):343-7. PubMed ID: 9438459
[TBL] [Abstract][Full Text] [Related]
6. Improved quality-control detection of false-negative Pap smears using the Autopap 300 QC system.
Marshall CJ; Rowe L; Bentz JS
Diagn Cytopathol; 1999 Mar; 20(3):170-4. PubMed ID: 10086244
[TBL] [Abstract][Full Text] [Related]
7. Neural-network-assisted analysis and microscopic rescreening in presumed negative cervical cytologic smears. A comparison.
Mango LJ; Valente PT
Acta Cytol; 1998; 42(1):227-32. PubMed ID: 9479345
[TBL] [Abstract][Full Text] [Related]
8. A more accurate measure of the false-negative rate of Papanicolaou smear screening is obtained by determining the false-negative rate of the rescreening process.
Renshaw AA; DiNisco SA; Minter LJ; Cibas ES
Cancer; 1997 Oct; 81(5):272-6. PubMed ID: 9349513
[TBL] [Abstract][Full Text] [Related]
9. PAPNET analysis of reportedly negative smears preceding the diagnosis of a high-grade squamous intraepithelial lesion or carcinoma.
Sherman ME; Mango LJ; Kelly D; Paull G; Ludin V; Copeland C; Solomon D; Schiffman MH
Mod Pathol; 1994 Jun; 7(5):578-81. PubMed ID: 7937724
[TBL] [Abstract][Full Text] [Related]
10. Computer-assisted rescreening of clinically important false negative cervical smears using the PAPNET Testing System.
Rosenthal DL; Acosta D; Peters RK
Acta Cytol; 1996; 40(1):120-6. PubMed ID: 8604564
[TBL] [Abstract][Full Text] [Related]
11. Negative cervical smears before CIN 3/carcinoma. Reevaluation with the PAPNET Testing System.
Doornewaard H; van de Seijp H; Woudt JM; van der Graaf Y; van den Tweel JG
Acta Cytol; 1997; 41(1):74-8. PubMed ID: 9022729
[TBL] [Abstract][Full Text] [Related]
12. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection.
Ronnett BM; Manos MM; Ransley JE; Fetterman BJ; Kinney WK; Hurley LB; Ngai JS; Kurman RJ; Sherman ME
Hum Pathol; 1999 Jul; 30(7):816-25. PubMed ID: 10414501
[TBL] [Abstract][Full Text] [Related]
13. [The PAPNET system in the rescreening of negative cervical/vaginal smears. A study from the Imola cytology laboratory].
Ghidoni D; Fabbris E; Folicaldi S; Amadori A; Medri M; Bucchi L; Bondi A
Pathologica; 1998 Aug; 90(4):357-63. PubMed ID: 9793395
[TBL] [Abstract][Full Text] [Related]
14. Expression of the MN antigen in cervical papanicolaou smears is an early diagnostic biomarker of cervical dysplasia.
Liao SY; Stanbridge EJ
Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):549-57. PubMed ID: 8827360
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of cytological screening for cancers and precancerous lesions of the cervix].
Boman F; Duhamel A; Trinh QD; Deken V; Leroy JL; Beuscart R
Bull Cancer; 2003 Jul; 90(7):643-7. PubMed ID: 12957806
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the SurePath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study.
Fremont-Smith M; Marino J; Griffin B; Spencer L; Bolick D
Cancer; 2004 Oct; 102(5):269-79. PubMed ID: 15386329
[TBL] [Abstract][Full Text] [Related]
17. Changing spectrum of squamous cell abnormalities observed on papanicolaou smears in Mubarak Al-Kabeer Hospital, Kuwait, over a 13-year period.
Kapila K; George SS; Al-Shaheen A; Al-Ottibi MS; Pathan SK; Sheikh ZA; Haji BE; Mallik MK; Das DK; Francis IM
Med Princ Pract; 2006; 15(4):253-9. PubMed ID: 16763390
[TBL] [Abstract][Full Text] [Related]
18. Simulation of primary cervical cancer screening by the PAPNET system in an unscreened, high-risk community.
Michelow PM; Hlongwane NF; Leiman G
Acta Cytol; 1997; 41(1):88-92. PubMed ID: 9022732
[TBL] [Abstract][Full Text] [Related]
19. PAPNET computer-aided rescreening for detection of benign and malignant glandular elements in cervicovaginal smears: a review of 61 cases.
Sturgis CD; Isoe C; McNeal NE; Yu GH; DeFrias DV
Diagn Cytopathol; 1998 Apr; 18(4):307-11. PubMed ID: 9557269
[TBL] [Abstract][Full Text] [Related]
20. Papnet-assisted, primary screening of cervico-vaginal smears.
Duggan MA
Eur J Gynaecol Oncol; 2000; 21(1):35-42. PubMed ID: 10726616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
